Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial.

ABSTRACT:

Background

The primary analysis of the INBUILD trial showed that in subjects with progressive fibrosing interstitial lung diseases (ILDs), nintedanib slowed the decline in forced vital capacity (FVC) over 52 weeks. We report the effects of nintedanib on ILD progression over the whole trial.

Methods

Subjects with fibrosing ILDs other than idiopathic pulmonary fibrosis, who had ILD progression within the 24 months before screening despite management deemed appropriate in clinical practice, were randomised to receive nintedanib or placebo. Subjects continued on blinded randomised treatment until all subjects had completed the trial. Over the whole trial, mean±sd exposure to trial medication was 15.6±7.2 and 16.8±5.8 months in the nintedanib and placebo groups, respectively.

SUBMITTER: Flaherty KR 

PROVIDER: S-EPMC8927709 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature